Generative Artificial Intelligence Nurse Staffing Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Hawaii

About this trial

This study is guided by Maslach's Burnout Theory and with Normalization Process Theory supporting the implementation of the GAINS intervention by facilitating its integration into routine system-level practice. In Year 1, the investigative team will collaborate with hospital-based nursing leadership and key stakeholders to identify staffing-specific factors essential for operationalizing the GAINS AI model/intervention. In Year 1, the investigators will also conduct a survey amongst nursing staff to measure baseline burnout. In Year 2, the AI-staffing intervention will be implemented with the medical-surgical nursing float pool team. In Year 3, the investigators will first repeat the nurse burnout survey and second, expand the intervention to include the nursing assistant float pool team. In Year 4, the investigators will conduct the final burnout survey with nurses, assess feasibility of GAINS (target vs. actual staffing- nurses and nursing assistants), and assess preliminary efficacy of GAINS to reduce costs related to staffing. the investigators will compare outcomes at three time points (pre, mid, and post-intervention). Interviews with nurses, nursing assistants, unit nurse managers, and leadership will further explicate the intervention's acceptability, feasibility, and impact on burnout.

Eligibility criteria

Qualifiers

Registered nurses, nursing assistants, or key stakeholders

Employed by The Queen's Medical Center

Working at least 24 hours per week

Position associated with medical-surgical units where float pool nurses work

Disqualifiers

Employees working less than 24 hours per week at The Queen's Medical Center

Employees whose roles are not related to medical-surgical units

Trial design

Treatments tested in this trial

  • Generative Artificial Intelligence Nurse Staffing (GAINS) Intervention

Treatment groups

660 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators